BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Covington
AstraZeneca
Daiichi Sankyo
Citi
McKinsey
Chinese Patent Office
Harvard Business School
Chubb

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,231,906

« Back to Dashboard

Which drugs does patent 8,231,906 protect, and when does it expire?

Patent 8,231,906 protects MINIVELLE and is included in one NDA.

This patent has twenty patent family members in fourteen countries.
Summary for Patent: 8,231,906
Title:Transdermal estrogen device and delivery
Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.
Inventor(s): Mantelle; Juan (Miami, FL)
Assignee: Noven Pharmaceuticals, Inc. (Miami, FL)
Application Number:12/216,811
Patent Claim Types:
see list of patent claims
Delivery; Use;

Drugs Protected by US Patent 8,231,906

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Noven MINIVELLE estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 203752-005 Sep 23, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Noven MINIVELLE estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 203752-001 Oct 29, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Noven MINIVELLE estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 203752-003 Oct 29, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Noven MINIVELLE estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 203752-002 Oct 29, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Noven MINIVELLE estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 203752-004 Oct 29, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,231,906

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,724,310 Transdermal estrogen device and delivery ➤ Subscribe
9,730,900 Transdermal estrogen device and delivery ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,231,906

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2310001 ➤ Subscribe
European Patent Office 3173078 ➤ Subscribe
Hong Kong 1155942 ➤ Subscribe
Japan 2011527697 ➤ Subscribe
Japan 5676440 ➤ Subscribe
Japan 2015017118 ➤ Subscribe
Japan 6118774 ➤ Subscribe
Japan 2017039781 ➤ Subscribe
South Korea 20110039331 ➤ Subscribe
Mexico 2011000332 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
Deloitte
US Department of Justice
Argus Health
Harvard Business School
McKesson
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot